Intellia Therapeutics (NTLA) Earnings Date & Reports

Key Takeaways

• Analysts expect Q1 2026 EPS of -$0.92 and revenue of about $14 million.
• Cash reserves stood at $605.1 million at year-end 2025, providing runway into the second half of 2027.
• Q4 2025 results showed collaboration revenue of $23 million, beating estimates, with net loss narrowing to $95.8 million.
• Investors will watch updates on lonvo-z Phase 3 trial for hereditary angioedema (HAE) and nex-z programs for ATTR amyloidosis.
• Recent FDA lift of clinical holds signals positive momentum for late-stage trials.
• Historical post-earnings stock moves have been mixed, averaging a slight 1% gain in the session following reports.

Earnings Context and Why It Matters

Intellia Therapeutics, a leader in CRISPR-based gene editing, faces a pivotal moment as it advances toward potential first approvals. With no commercial products yet, quarterly results hinge on R&D progress, cash management, and clinical milestones rather than top-line sales. The upcoming Q1 2026 report, expected in late April or early May, comes amid renewed optimism from FDA resolutions on trial holds and robust cash reserves. For investors, this earnings will gauge burn rate sustainability and pipeline momentum in the competitive gene therapy space, where delays can pressure valuations. Recent beats in revenue and narrower losses underscore operational discipline amid high R&D spend.

Earnings Expectations

Wall Street anticipates a consensus EPS loss of -$0.92 for Q1 2026, with revenue forecasts around $13.5-14.8 million, primarily from collaborations. This reflects ongoing pre-revenue status, with focus shifting to operating metrics. In Q4 2025, Intellia reported EPS of -$0.83, surpassing estimates of -$0.97, and revenue of $23 million versus $12 million expected. R&D expenses fell to $88.7 million from $116.9 million year-over-year, signaling efficiency gains.

Key areas include cash burn—net loss improved to $95.8 million in Q4—and updates on enrollment in nex-z trials for transthyretin amyloidosis (ATTR). Investors eye guidance on the $605 million cash pile and progress toward lonvo-z HAELO Phase 3 topline data by mid-2026. Past reactions show beats often lift shares modestly, while pipeline delays weigh heavier.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Heading into Q1 2026 earnings, sentiment leans cautiously optimistic, buoyed by Q4 beats and FDA progress on nex-z trials. Shares have shown resilience, with historical post-earnings moves averaging +1% in the first day, though biotech volatility amplifies reactions to pipeline news. Risks include higher-than-expected burn or delays in HAELO enrollment, potentially pressuring the stock amid broader sector pressures.

Forward Outlook and Key Factors to Monitor

Following Q1 results, attention will center on cash utilization and runway confirmation into H2 2027. With $605 million on hand, investors should track quarterly burn against R&D investments in lonvo-z and nex-z.

Pipeline catalysts loom large: HAELO Phase 3 topline for lonvo-z by mid-2026, with BLA filing in H2 2026 and potential launch in H1 2027. MAGNITUDE-2 enrollment for nex-z in ATTRv-PN aims for completion in H2 2026, post-FDA hold lift. Resolution on the ATTR-CM hold remains critical.

Broader dynamics include partnership revenues from Regeneron and AvenCell, margin trends in collaborations, and competitive gene editing advances. Monitor enrollment rates, safety data, and regulatory engagements for signals on commercialization timelines.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations